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Introduction
Rhabdomyosarcoma (RMS) is the most common paediatric soft-tissue sarcoma and accounts 
for approximately 4 to 5% of all childhood malignancies. The disease may appear in any 
organ or tissue, and can metastasise to lung, bone marrow, bone, and lymph nodes. Current 
treatment regimens incorporate surgery, chemotherapy, and radiotherapy (RT). Using this 
multimodality approach, the cure rates for RMS have steadily increased from only 25% in the 
1970s to 70% in the 1990s.1-3 The prognostic factors include: the primary site, the histology, 
the age at diagnosis, the clinical stage and grouping.3-6 The Intergroup Rhabdomyosarcoma 
Study Group (IRSG) has conducted four consecutive clinical trials (IRS-I, 1972-78; IRS-II, 1978-
84; IRS-III, 1984-91; IRS-IV, 1991-97),3,7-9 with treatment outcomes that compared favourably 
with other large international studies.3,10-12 In Hong Kong, we had largely adopted the IRSG 
treatment regimens. The aim of this study was to review corresponding treatment outcomes 
of children with RMS diagnosed at Queen Mary Hospital over the past 16 years.
	 Objectives	 To	 review	 the	 treatment	 outcome	 of	 rhabdomyosarcoma	 in	
Hong	Kong	Chinese	children.
	 Design	 Retrospective	review.
	 Setting	 University	teaching	hospital,	Hong	Kong.
	 Patients	 Consecutive	 cases	 of	 rhabdomyosarcoma	 diagnosed	 and	
treated	 by	 the	 Department	 of	 Paediatrics	 and	 Adolescent	
Medicine	 of	 Queen	 Mary	 Hospital	 between	 1989	 and	 2005.	
Each	patient	was	staged	and	treated	according	to	the	Intergroup	
Rhabdomyosarcoma	Study	guidelines.
 Main outcome measures	 Overall	and	event-free	survival	rates,	and	toxicity	data.
	 Results	 Of	19	patients	(8	males	and	11	females),	14	(74%)	were	younger	
than	10	years	old.	The	median	age	at	diagnosis	was	6	(range,	0.5-17)	
years.	Primary	sites	of	rhabdomyosarcoma	included:	the	head	and	
neck	(n=8;	6	classified	as	cranial	parameningeal),	genitourinary	
(3),	 extremity	 (3),	 pelvis	 (3),	 and	 trunk	 (2).	Thirteen	 (68%)	had	
embryonal	and	six	(32%)	had	alveolar	histology.	Two,	2,	9,	and	6	
were	classified	as	belonging	to	Intergroup	Rhabdomyosarcoma	
Study	groups	1,	2,	3,	and	4,	respectively.	Respective	5-year	overall	
and	event-free	survival	rates	of	the	entire	cohort	were	49%	(95%	
confidence	interval,	26-73%)	and	32%	(10-55%),	with	a	median	
follow-up	of	3.4	(range,	0.2-16.7)	years.	In	non-metastatic	cases	
(Intergroup	Rhabdomyosarcoma	Study	groups	1-3),	 the	5-year	
overall	survival	rate	was	66%	(95%	confidence	interval,	39-93%)	
and	in	metastatic	cases	(group	4)	it	was	17%	(0-46%).	The	5-year	
overall	survival	rate	for	patients	aged	less	than	10	years	was	60%	
(95%	 confidence	 interval,	 33-87%)	 compared	 to	 20%	 (0-55%)	
in	 those	 aged	 10	 years	 and	over.	 Significant	 treatment-related	
toxicities	 including	 myelosuppression,	 infections,	 peripheral	
neuropathy,	and	second	cancers	were	encountered.
	 Conclusions	 Treatment	 outcome	 of	 rhabdomyosarcoma	 in	 this	 cohort	 of	
Chinese	 children	 was	 less	 favourable	 than	 that	 reported	 in	
international	 studies.	Whilst	 the	main	 reason	 could	 have	 been	
related	 to	 the	 high	 proportion	 of	 metastatic	 cases,	 also	 non-
metastatic	 cases	 faired	 worse.	 Improved	 outcomes	 may	 be	
achieved	by	advances	 in	multidisciplinary	 (paediatric	oncology,	
pathology,	 radiotherapy,	 and	 surgery)	 management	 and	
supportive	care.
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Methods
Patients
Consecutive patients younger than the age of 18 
years, with RMS diagnosed and treated at Queen 
Mary Hospital between 1989 and 2005, were identified 
from our clinical database. Charts were reviewed to 
extract demographic data, clinical features, treatment 
protocols, toxicity, and outcomes. Twenty-two 
patients with RMS presented to our hospital. Three 
patients were excluded because they subsequently 
received treatment in other medical centres; the 
remaining 19 formed the subjects of this study. 
Seventeen children were treated with the IRS-IV 
protocol,3 one patient with the IRS-V protocol13 and 
one with the International Society of Paediatric 
Oncology Malignant Mesenchymal Tumour (SIOP 
MMT)–89 protocol.11
Definitions
Overall survival (OS) was defined as the time from 
the start of treatment to death from any cause. Events 
were defined as disease relapse or second neoplasm 
after complete remission or death from any cause. 
The censor date was 31 March 2006. Patients were 
assigned presurgical staging based on the primary 
tumour site, size, presence or absence of clinically 
evident lymph node involvement and/or metastatic 
disease, according to the IRSG presurgical staging 
classification.3 Patients were also assigned clinical 
grouping according to the surgical-pathological 
system of the IRSG postsurgical grouping 
classification.3 Toxicities were evaluated by the 
National Cancer Institute–Common Toxicity Criteria 
(NCI-CTC) version 2.0.14 Histological diagnoses of 
all 19 RMS cases were validated by two pathologists 
(SKC, TWHS), who retrieved and reviewed the original 
diagnostic slides, according to the International 
Classification of Rhabdomyosarcoma.4
Statistical methods
Overall survival and event-free survival (EFS) rates 
were calculated using the Kaplan-Meier method. 
Since our study involved a relatively small number of 
patients in a single institution, subgroup analysis of 
known prognostic factors was not performed.
Results
Patient characteristics
Fourteen (74%) of the 19 patients were less than 10 
years old; their median age at diagnosis was 6 (range, 
0.5-17) years, eight were male and 11 female. One child 
had neurofibromatosis. Our patients had diverse 
clinical presentations, depending on the site of the 
primary tumour, ranging from an indolent painlessly 
enlarging mass to an acute onset with cranial nerve 
palsy, spinal cord compression, bleeding, and gastro-
intestinal or urinary tract obstruction. The most 
common primary site was the head and neck (8 
cases); six of the latter sites were classified as cranial 
parameningeal (Table). Other primary sites were 
genitourinary (n=3), extremity (n=3), pelvis (n=3), and 
trunk (n=2). Tumour size was greater than 5 cm in 
diameter in 47% of cohort, and over two thirds had 
evidence of local tissue invasion (T2) at diagnosis. 
Thirty-two percent did not manifest regional lymph 
nodes, 47% had manifested regional lymph node 
involvement and in 21% the lymph node status was 
unknown (Table). Thirteen (68%) of 19 patients had 
embryonal and six had alveolar histology. Four, 3, 6, 
and 6 patients were classified as belonging to IRS 
stage I, II, III, and IV groups, respectively. The distant 
metastatic sites of the six stage IV cases were the lung 
		#		Yuan	et	al	#
118	 Hong	Kong	Med	J		Vol	14	No	2	#	April	2008	#		www.hkmj.org
(50%), bone (33%), and lymph nodes (33%). Median 
follow-up duration was 3.4 (range, 0.2-16.7) years.
Treatment
Multimodality treatment comprising chemotherapy, 
surgery, and RT was used for our RMS patients; the 
majority of whom received full-dose chemotherapy 
as specified by the corresponding chemotherapy 
protocol (mainly IRS-IV regimen, Table), except that 
the dose was reduced (to 50-75%) in two infants. 
According to the IRS-IV protocol, we adopted 
the standard treatment arm—VA (vincristine and 
actinomycin D) for stage I group 1, stage I group 2 orbit, 
stage I group 1 or 2 paratesticular tumour; and VAC 
(vincristine, actinomycin D, and cyclophosphamide) 
for all other categories of non-metastatic RMS. 
Granulocyte–colony stimulating factor was not 
given prophylactically following each cycle of VAC, 
but was added as rescue therapy (5 mg/kg/day) 
when the patient developed neutropenic fever. 
Significant toxicity such as severe oral mucositis 
was encountered, particularly during concurrent RT 
and chemotherapy. Interruption and delay to the 
scheduled chemotherapy with subsequent reduction 
of the dose of actinomycin D was deemed necessary 
in three (16%) of the patients with persistent mucositis 
(NCI-CTC grade 4). Vincristine was discontinued 
in two patients who developed severe peripheral 
neuropathy (NCI-CTC grade 4).
 Only five of 19 patients had surgical resection of 
the primary tumour at diagnosis; two (11%) achieved 
complete resection (IRS group 1) whilst two (11%) 
had microscopic residual disease (IRS group 2). The 
majority had a biopsy only at diagnosis; nine (47%) 
were in group 3, and six (32%) in group 4. Overall, 
10 (53%) patients underwent surgical resection of the 
primary tumour, and complete resection was achieved 
in seven, whereas gross residual disease remained in 
three (Table). Surgical resection was not feasible in 
five of the six children with cranial parameningeal 
disease (Table).
Patient No. Age (yrs) Sex Site* Histology† IRS stage‡ IRS group Treatment regimen Overall 
survival (yrs)
Event-free 
survival (yrs)
Status††
Chemotherapy§ Radiotherapy❘❘ Surgery¶ ABMT**
Type Timing (weeks) Dose (Gy) Type Timing (weeks)
1 17.2 F GU 1 IV (T2b N1 M1) 4 1 3 16 54 ND - - 0.9 0.6 DOD
2 17.4 M GU 2 I (T1a N0 M0) 1 1 ND - - 1 D0 - 5.7 5.7 NED
3 0.5 M Trunk 1 IV (T2b N1 M1) 4 1 3 36 50.4 2 D0 Yes 3.6 2.1 DOD
4 12.2 F PM 2 III (T2b N1 M0) 3 1 3 7 50.4 ND - - 2.4 1.2 DOD
5 0.6 F H&N 2 I (T1a N0 M0) 3 1 ND - - 1 10 - 3.4 3.4 NED
6 10.0 M Pelvis 1 IV (T2b N1 M1) 4 1 1 D0 24 ND - - 0.2 0.2 DOD
7 1.3 M Trunk 1 II (T1a N0 M0) 2 1 1 9 41.4 1 D0 - 9.6 9.6 NED
8 3.0 F PM 1 IV (T2a N0 M1) 4 1 2 3 50.4 ND - - 0.7 0.7 DOI
9 2.2 F PM 1 III (T2a N1 M0) 3 1 3 9 50.4 ND - - 6.1 3.7 NED
10 1.8 F Extremity 1 II (T2a Nx M0) 2 1 1 10 50.4 1 D0 - 3.4 2.4 DOD
11 8.6 M PM 1 III (T2b N0 M0) 3 1 2 3 50 ND - - 4.9 4.1 AWD
12 5.7 F Pelvis 1 III (T2b Nx M0) 3 2 1 16 36 2 10 - 1.2 1.2 NED
13 9.7 F Extremity 2 IV (T1b Nx M1) 4 1 1 NA * 1 NA - 16.7 16.7 NED
14 4.3 M PM 1 III (T2b N1 M0) 3 1 3 10 50.4 ND - - 6.1 6.1 NED
15 16.0 M Pelvis 2 IV (T2 N1 M1) 4 1 1 NA 54 ND - Yes 1.8 1.8 DOD
16 6.8 M GU 1 I (T2b N0 M0) 1 1 ND - - 1 D0 - 7.5 7.5 NED
17 9.3 F H&N 1 I (T2a N1 M0) 3 1 1 10 50.4 ND - - 1.4 1.4 DOI
18 2.7 F Extremity 2 III (T2a N1 M0) 3 1 1 23 41.4 1 20 Yes 5.8 1.1 NED
19 3.6 F PM 1 II (T2a Nx M0) 3 3 1 NA NA 2 NA Yes 3.1 2.2 DOD
TABLE. Demographic and clinical features, treatment regimens, and outcomes of the rhabdomyosarcoma patients
* Primary sites: GU=genitourinary (non-bladder/prostate); H&N=head and neck, non-parameningeal; PM=parameningeal
† Histology: 1=embryonal; 2=alveolar
‡ IRS denotes Intergroup Rhabdomyosarcoma Study
§ Chemotherapy protocol: 1=IRS-IV; 2=IRS-V; 3=International Society of Paediatric Oncology Malignant Mesenchymal Tumour (SIOP MMT)–89 protocol
❘❘ Radiotherapy (RT) type: 1=conventional RT; 2=intensity-modulated RT; 3=3D-conformal RT; *=including right thigh 50.4 Gy, boost local 32 Gy, right lung 18 Gy; 
ND=not done; NA=information not available; D0=at diagnosis
¶ Surgery: 1=complete resection; 2=partial resection; ND=not done; NA=information not available; D0=at diagnosis
** ABMT denotes autologous bone marrow transplantation
†† Status: DOD=died of disease, NED=no evidence of disease, DOI=died of infection, AWD=alive with disease
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 Sixteen (84%) of the 19 patients received 
RT; the exceptions being two with stage I 
group 1 disease and an infant who had delayed 
complete resection of a right nasal ala tumour 
(Table). Over the entire study period, three 
types of RT were administered—9 (56%) of 16 
patients received conventional RT, two received 
intensity-modulated RT, and five were given 
three-dimensional conformal RT. Most patients 
received total RT dosages of between 41.4 and 50.4 Gy. 
Radiotherapy was usually administered after the 
induction phase of chemotherapy, at about 9 and 
16 weeks of treatment. Cranial parameningeal 
cases that showed evidence of either skull base 
erosion, intracranial extension or cranial nerve 
palsy commenced RT within the first few weeks of 
treatment concurrent with chemotherapy (Fig 1). 
Four patients, including one with metastases and 
three relapsed patients, underwent autologous 
bone marrow transplantation; only one of whom 
remains alive.
Survival and outcome
Five-year OS and EFS rates of the whole cohort of 
patients were 49% (95% confidence interval [CI], 26-
73%) and 32% (95% CI, 10-55%), respectively (Fig 2). 
Patients with non-metastatic tumours (IRS group 1-
3) had much better outcomes than the others (IRS 
group 4). The 5-year OS rate was 66% (95% CI, 39-93%) 
in non-metastatic cases, compared to 17% (95% CI, 
0-46%) in metastatic cases (Fig 3a). Five-year OS rate 
for patients less than 10 years old was 60% (95% CI, 
33-87%) compared to 20% (95% CI, 0-55%) for those 
who were older (Fig 3b). There was no difference in 
survival between those with embryonal and alveolar 
histology tumours. The series of patients was too 
small to allow meaningful analysis of the impact of 
potential prognostic factors, such as primary tumour 
site, IRS staging and grouping.
 There were 11 treatment failures in 19 
patients—disease relapse (n=7), death due to severe 
infection (n=2), second malignant neoplasm (n=2). 
Patient No. Age (yrs) Sex Site* Histology† IRS stage‡ IRS group Treatment regimen Overall 
survival (yrs)
Event-free 
survival (yrs)
Status††
Chemotherapy§ Radiotherapy❘❘ Surgery¶ ABMT**
Type Timing (weeks) Dose (Gy) Type Timing (weeks)
1 17.2 F GU 1 IV (T2b N1 M1) 4 1 3 16 54 ND - - 0.9 0.6 DOD
2 17.4 M GU 2 I (T1a N0 M0) 1 1 ND - - 1 D0 - 5.7 5.7 NED
3 0.5 M Trunk 1 IV (T2b N1 M1) 4 1 3 36 50.4 2 D0 Yes 3.6 2.1 DOD
4 12.2 F PM 2 III (T2b N1 M0) 3 1 3 7 50.4 ND - - 2.4 1.2 DOD
5 0.6 F H&N 2 I (T1a N0 M0) 3 1 ND - - 1 10 - 3.4 3.4 NED
6 10.0 M Pelvis 1 IV (T2b N1 M1) 4 1 1 D0 24 ND - - 0.2 0.2 DOD
7 1.3 M Trunk 1 II (T1a N0 M0) 2 1 1 9 41.4 1 D0 - 9.6 9.6 NED
8 3.0 F PM 1 IV (T2a N0 M1) 4 1 2 3 50.4 ND - - 0.7 0.7 DOI
9 2.2 F PM 1 III (T2a N1 M0) 3 1 3 9 50.4 ND - - 6.1 3.7 NED
10 1.8 F Extremity 1 II (T2a Nx M0) 2 1 1 10 50.4 1 D0 - 3.4 2.4 DOD
11 8.6 M PM 1 III (T2b N0 M0) 3 1 2 3 50 ND - - 4.9 4.1 AWD
12 5.7 F Pelvis 1 III (T2b Nx M0) 3 2 1 16 36 2 10 - 1.2 1.2 NED
13 9.7 F Extremity 2 IV (T1b Nx M1) 4 1 1 NA * 1 NA - 16.7 16.7 NED
14 4.3 M PM 1 III (T2b N1 M0) 3 1 3 10 50.4 ND - - 6.1 6.1 NED
15 16.0 M Pelvis 2 IV (T2 N1 M1) 4 1 1 NA 54 ND - Yes 1.8 1.8 DOD
16 6.8 M GU 1 I (T2b N0 M0) 1 1 ND - - 1 D0 - 7.5 7.5 NED
17 9.3 F H&N 1 I (T2a N1 M0) 3 1 1 10 50.4 ND - - 1.4 1.4 DOI
18 2.7 F Extremity 2 III (T2a N1 M0) 3 1 1 23 41.4 1 20 Yes 5.8 1.1 NED
19 3.6 F PM 1 II (T2a Nx M0) 3 3 1 NA NA 2 NA Yes 3.1 2.2 DOD
TABLE. Demographic and clinical features, treatment regimens, and outcomes of the rhabdomyosarcoma patients
* Primary sites: GU=genitourinary (non-bladder/prostate); H&N=head and neck, non-parameningeal; PM=parameningeal
† Histology: 1=embryonal; 2=alveolar
‡ IRS denotes Intergroup Rhabdomyosarcoma Study
§ Chemotherapy protocol: 1=IRS-IV; 2=IRS-V; 3=International Society of Paediatric Oncology Malignant Mesenchymal Tumour (SIOP MMT)–89 protocol
❘❘ Radiotherapy (RT) type: 1=conventional RT; 2=intensity-modulated RT; 3=3D-conformal RT; *=including right thigh 50.4 Gy, boost local 32 Gy, right lung 18 Gy; 
ND=not done; NA=information not available; D0=at diagnosis
¶ Surgery: 1=complete resection; 2=partial resection; ND=not done; NA=information not available; D0=at diagnosis
** ABMT denotes autologous bone marrow transplantation
†† Status: DOD=died of disease, NED=no evidence of disease, DOI=died of infection, AWD=alive with disease
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Relapse was local in one (14%) patient, regional in 
two (29%) and combined local and distant relapse in 
four (57%). The median time interval from diagnosis 
to relapse was 25 months. The five relapsed patients 
died. One patient was alive with progressive disease, 
and another who underwent an autologous bone 
marrow transplant survived, with no evidence of 
disease.
0
0.0 2.5 5.0 7.5 10.0 12.5 15.0 17.5
25
50
75
100
Overall survival (49%)
Event-free survival (32%)
%
Years
FIG 2.  Overall and event-free survival of the 19 rhabdomyosarcoma patients
FIG 1a. Radiotherapy planning for a cranial parameningeal (para-
pharyngeal) rhabdomyosarcoma in a 3-year-old patient
The magenta line outlined the gross tumour volume (GTV), the 
red line outlined the planning target volume (PTV), the yellow and 
cyan lines represented the 100% and 90% isodoses, respectively; SC 
denotes spinal cord
FIG 1b. Complete remission of the tumour after chemotherapy 
and radiotherapy; no surgical resection was performed
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Toxicity data
Significant toxicity was encountered with the 
VAC treatment regimen. According to the NCI-
CTC version 2.0,14 16 (86%) patients experienced 
myelosuppression with five (26%) reaching grade 
4 severity. Infections such as neutropenic fever 
occurred in almost every patient; multiple episodes 
were frequently encountered by individual patients. 
Severe septicaemia associated with profound 
neutropenia developed in two patients resulting 
in their death; one during the IRS-IV treatment 
regimen and one after the last cycle of VAC cycle 
0
0.0 2.5 5.0 7.5 10.0 12.5 15.0 17.5
25
50
75
100
Non-metastatic (n=13, 66%)
Metastatic (n=6, 17%)
%
Years
FIG 3.  (a) Survival of non-metastatic and metastatic rhabdomyosarcoma. (b) Impact of age on survival of rhabdomyosarcoma
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100
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Age ≥10 years (n=5, 20%)
Age <10 years (n=14, 60%)
(a)
(b)
		#		Yuan	et	al	#
122	 Hong	Kong	Med	J		Vol	14	No	2	#	April	2008	#		www.hkmj.org
before recovery from myelosuppression, three (16%) 
had severe (CTC grade 4) mucositis, four (21%) had 
moderate-to-severe vincristine-induced neuropathy 
(CTC grade 3 or 4), and four (21%) had renal toxicity. 
Two (11%) patients developed second neoplasms 
(both undifferentiated sarcomas) at 44 and 49 months 
after initial diagnosis of RMS.
Discussion
The primary aims of this study were to review the 
Hong Kong experience of treating RMS, a rare group 
of childhood tumours, and identify potential areas 
for improved management. The 5-year OS and EFS 
rates in this RMS cohort in Chinese children treated 
in a single institution were 49% and 32%, respectively. 
The Kaplan-Meier curve for EFS indicated that most 
relapses occurred within 2.5 years of diagnosis. 
The late events were second malignant neoplasms 
occurring 3.7 and 4.1 years post-diagnosis. Survival 
outcome appeared inferior to those reported by IRSG 
and in other international studies3,8,11,12; the outcomes 
of our patients belonging to different IRS groups 
were examined to identify possible reasons.
 The higher percentage (32%) of patients with 
metastatic RMS (IRS group 4) in our cohort compared 
to the average of 15% reported in international 
studies8,15,16 was the most likely factor accounting 
for our inferior OS. A marked difference in survival 
was observed when the patients were separated 
according to metastatic (17%) and non-metastatic 
(66%) status (Fig 3a), since metastatic RMS confers 
poor survival worldwide. The 3-year OS and EFS rates 
were 39% and 25%, respectively in the 127 patients 
with metastatic RMS treated by the IRS-IV study.17 
In the same study, a subgroup of patients with 
embryonal histology and two or fewer metastatic 
sites had higher OS (47%) and EFS (40%) rates.17 A 
retrospective review of 19 patients with metastatic 
RMS treated at the Hospital for Sick Children in 
Toronto over a 10-year period also identified a subset 
of patients (<10 years old with embryonal histology 
and metastases confined to the lungs) with a much 
more favourable prognosis.18 The 5-year OS and EFS 
rates of 174 metastatic RMS patients participating in 
two consecutive European studies (MMT4-89 and 
MMT4-91) were 24% and 20%, respectively. However, 
those with fewer than two unfavourable factors 
(unfavourable site and age, as well as bone or bone 
marrow metastases) had respective 5-year EFS and 
OS rates of 40% and 47%, compared to less than 10% 
survival in the remainder.19 In our series, one of the 
six IRS group 4 patients (case 13, Table) presenting at 
the age of 9 years with alveolar RMS of an extremity 
and pulmonary metastases was the only long-term 
survivor. Other patients had multiple adverse factors 
such as unfavourable age (>10 years or <1 year) or 
distant metastases at multiple sites.
 Among the nine IRS group 3 patients 
(unresectable tumours or those with incomplete 
resection), all except two were in the head and neck 
region, of which five were cranial parameningeal. 
Among the five patients with parameningeal tumours, 
two died of the disease whilst three achieved 
complete remission. However, only one remained 
in continuous complete remission; the other two 
developed a second cancer at or near the radiation 
field. One patient was salvaged with chemotherapy 
and complete resection of the second tumour, whilst 
the other had progressive disease. Importantly, 
non-metastatic parameningeal tumours can be 
treated successfully by combined chemotherapy 
and radiation to the initial tumour volume, without 
the need for aggressive surgical resection.20,21 Again, 
our results were inferior to the 5-year OS rate of 
73% (95% CI, 70-77%) for 611 patients with localised 
parameningeal tumours treated in the IRS II-IV 
studies.20 Improvement in supportive care as well 
as advances in RT techniques22 (accurately defining 
the tumour target volume with fusion of magnetic 
resonance images) are important in the treatment of 
this group of patients.
 Most treatment failures in our patients were 
in disease relapses at local, regional, or distant 
sites. In both IRS-III and IRS-IV trials, local failure 
risk exceeded the risk of distant metastases as a 
first failure event.3,9 The IRS-V study explored the 
role of surgery in reducing local failures after 
induction chemotherapy (12 weeks for most group 
3 patients).13 Postoperative RT is required but the 
dose is determined by resection margin status. 
In our series, complete surgical resection was 
mainly achieved in IRS group 1 and 2 patients, 
who enjoyed excellent survival. The feasibility 
of surgical resection of tumours after induction 
chemotherapy, while also preserving form and 
function, should always be explored rigorously in 
individual patients.
 Age has been shown to be an important 
prognostic factor for certain subgroups of RMS.23 A 
significant difference in survival between patients 
aged less than 10 years and those who were older (Fig 
3b) was noted. However, arguably older patients in 
our series had more advanced and invasive disease. 
Histological subtype has been consistently shown 
to be one of the most important prognostic factors 
for RMS; alveolar tumours generally have worse 
survival outcomes.23 There was no survival difference 
between patients with embryonal and alveolar RMS 
in our cohort of patients, very likely due to the small 
numbers and the advanced clinical grouping (3 or 4) 
of the majority (75%) with embryonal histology.
 Significant treatment-related toxicities were 
observed in the 19 patients of our series, treated 
mainly according to the IRS-IV protocol. Intensified 
therapy used in IRS-IV resulted in myelosuppression 
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(>90%) with subsequent episodes of severe infections 
(55%) and death (1%), severe renal toxicity (2%) and 
second cancers in 10 (1.1%) of 883 patients.3 We 
observed frequent occurrence of myelosuppression 
(86%), severe mucositis (16%), renal toxicity (21%), and 
severe vincristine-induced neuropathy (21%). Two 
patients died of severe septicaemia. In two patients 
with parameningeal tumours, following relatively 
short latency periods, second malignant neoplasms 
(both undifferentiated sarcomas) developed within or 
near the radiation field. The latter were possibly due 
to the use of alkylating agents and RT. Development 
of appropriate supportive care is essential to minimise 
complications of this treatment regimen.
 In conclusion, this retrospective review of a 
series of childhood RMS patients and experience in 
treating this cancer in Hong Kong identified potential 
aspects of management deserving improvement. 
These included post-chemotherapy supportive 
care, surgical resection of residual tumours, and 
usage of contemporary RT strategies, all of which 
should be targeted for continual development in the 
management of RMS.
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